MANNKIND CORP

MNKDNASDAQ

🏆 #2164 by market capEarnings Nov 4US Equity

$3.90▲ $0.06 (+1.49%)

Live

1h▲ 0.2%

24h▲ 1.5%

7d▼ 5.6%

14d▲ 1.2%

30d▼ 3.3%

1y▲ 6.5%

🏦Market Cap

$1.24B

Small Cap

📈Revenue Growth (YoY)

+30.5%

High Growth

📊Gross Margin

76.8%

High

💵FCF Margin

12.7%

Healthy

⚖️P/S Ratio

3.3x

Fair

Otter Score

Weak

Trading Snapshot

Day Range: $3.84 – $3.93
52-Week Range: $2.23 – $6.51
Volume: $2.33B
Avg Volume: $1.64B
Shares Outstanding: 319.4M
Next Earnings: Oct 23, 2026

Fundamentals Snapshot

Annual Revenue: $349M
Last Q Revenue: $109M
P/E Ratio: —
P/S Ratio: 3.3x
EPS (TTM): $-0.14
Dividend Yield: —

Why Investors Own MNKD

✓High-growth profile — revenue up +5.7% YoY with expanding US Equity exposure.
✓Healthy economics — 68% gross margin and 13% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$349M▲ +6.8% YoY

Gross Margin (TTM)

67.8%▲ +3.6% YoY

Operating Income (TTM)

$40M▲ +6.8% YoY

Free Cash Flow (TTM)

$45M▲ +6.8% YoY

About MANNKIND CORP

MannKind Corporation operates as a biopharmaceutical firm, primarily focused on innovating and bringing to market respiratory-delivered treatments. Its efforts are directed towards tackling endocrine system disorders and rare lung conditions within the U.S. market. The company's key product is Afrezza, an inhaled insulin designed to improve glycemic control for adults managing diabetes. MannKind also actively markets Thyquidity, promoting it to adult and pediatric endocrinologists and other healthcare professionals for the treatment of hypothyroidism. In terms of collaborations, MannKind holds a strategic licensing and partnership agreement with United Therapeutics Corporation. Furthermore, it is collaborating with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI (aviptadil), which is a synthetic variant of human vasoactive intestinal peptide intended to shield cells from inflammatory processes. Established in 1991, MannKind Corporation's corporate offices are located in Westlake Village, California.

🦦